Ana-Maria de Roda Husman, PhD; Maarten Koot, PhD; Marion Cornelissen, PhD; Ireneus P.M. Keet, MD, PhD; Margreet Brouwer, BSc; Silvia M. Broersen, BSc; Margreet Bakker, BSc; Marijke T.L. Roos, BSc; Maria Prins, MSc; Frank de Wolf, MD, PhD; Roel A. Coutinho, MD, PhD; Frank Miedema, PhD; Jaap Goudsmit, MD, PhD; Hanneke Schuitemaker, PhD
Heterozygosity for a 32-nucleotide deletion in the C-C chemokine receptor 5 gene (CCR5 delta32) is associated with delayed disease progression in persons infected with HIV-1.
To compare the predictive value of CCR5 genotype with that of established markers in the clinical course of HIV-1 infection.
Retrospective longitudinal study and nested case–control study. The latter included only long-term survivors, who were individually matched with progressors.
Amsterdam, the Netherlands.
364 homosexual men with HIV-1 infection.
Polymerase chain reaction was used for CCR5 genotyping. Univariate and multivariate Cox proportional-hazard analyses were done for disease progression with CCR5 genotype, CD4+ T-lymphocyte counts, T-lymphocyte function, HIV-1 biological phenotype (syncytium-inducing or non-syncytium-inducing HIV-1), and viral RNA load in serum as covariates.
In the case–control study, 48% of long-term survivors were heterozygous for CCR5 delta32 compared with 9% of progressors (odds ratio, 6.9 [95% CI, 1.9 to 24.8]). In the total study sample, CCR5 delta32 heterozygotes had significantly delayed disease progression (P < 0.001; relative hazard, 0.4 [CI, 0.3 to 0.6]), a 1.5-fold slower decrease in CD4+ T-lymphocyte count (P = 0.01), and a 2.6-fold lower viral RNA load (P = 0.01) at approximately 2.3 years after seroconversion compared with CCR5 wild-type homozygotes. At the end of the study, both groups showed the same prevalence of syncytium-inducing HIV-1, but CCR5 delta32 heterozygotes had a delayed conversion rate. The protective effect of CCR5 delta32 heterozygosity was stronger in the presence of only non-syncytium-inducing HIV-1. The CCR5 genotype predicted disease progression independent of viral RNA load, CD4 T-lymphocyte counts, T-lymphocyte function, and HIV-1 biological phenotype.
The addition of CCR5 genotype to currently available laboratory markers may allow better estimation of the clinical course of HIV-1 infection.
de Roda Husman A, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, et al. Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection. Ann Intern Med. ;127:882–890. doi: 10.7326/0003-4819-127-10-199711150-00004
Download citation file:
Published: Ann Intern Med. 1997;127(10):882-890.
HIV, Infectious Disease.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use